| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
VEGFR2 (vascular endothelial growth factor receptor 2); calcium channels; NO synthase.
|
|---|---|
| ln Vitro |
Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating the VEGFR2 signal pathway in colorectal cancer. It inhibits tonic contractions induced by high K⁺ and phenylephrine (PE) in rat aorta with IC₅₀ values of 0.30 mM and 0.38 mM, respectively. It has antifungal and vasorelaxant effects. It induces lipid peroxidation and metabolic disorder through ROS overproduction. It also exhibits nematocidal and sedative activities.
|
| ln Vivo |
Ethyl cinnamate suppresses tumor growth through anti-angiogenesis in colorectal cancer models. It has vasorelaxant effects on smooth muscles of the rat aorta. It is not toxic to mammals because it is quickly metabolized in the liver. The compound inhibits locomotor activity in insects, possibly due to inhibition of energy metabolism. Its oral activity makes it suitable for in vivo administration.
|
| Enzyme Assay |
Vasorelaxant activity is assessed using isolated rat aortic rings. Aorta segments are mounted in organ baths, pre-contracted with high K⁺ or phenylephrine (PE), and cumulative concentrations of ethyl cinnamate are added. The relaxation response is recorded and IC₅₀ values are calculated. For VEGFR2 inhibition, kinase assays using recombinant VEGFR2 and ATP are performed. For antifungal activity, standard broth microdilution assays are used.
|
| Cell Assay |
For cell-based studies, colorectal cancer cell lines are cultured and treated with ethyl cinnamate. Cell proliferation, migration, and angiogenesis are assessed. VEGFR2 signaling pathway components are analyzed by Western blot. For vasorelaxation studies, primary smooth muscle cells may be used in calcium imaging or patch-clamp experiments. For anticancer studies, apoptosis and cell cycle analysis are performed using flow cytometry.
|
| Animal Protocol |
In vivo tumor growth studies use mouse xenograft models of colorectal cancer. Ethyl cinnamate is administered orally to tumor-bearing mice. Tumor volume is measured over time. Angiogenesis is assessed by immunohistochemistry for CD31 or other vascular markers. For vasorelaxation studies, animal models of hypertension may be used. The compound's effects on blood pressure and vascular function are monitored.
|
| ADME/Pharmacokinetics |
Ethyl cinnamate is rapidly metabolized in the liver, contributing to its low toxicity in mammals. It is orally active. The compound is used as a food flavor and cosmetic additive. It is also an excellent clearing reagent for mammalian tissues. It should be stored as a powder at -20°C for up to 3 years. The compound is soluble in organic solvents and is used in analytical and research applications.
|
| Toxicity/Toxicokinetics |
Ethyl cinnamate is not toxic to mammals because it is quickly metabolized in the liver. It is generally recognized as safe for use as a food flavor and cosmetic additive. In vitro, it can lead to damage of the cell membrane system and metabolic disorder through inducing lipid peroxidation via ROS overproduction. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Ethyl cinnamate is an alkyl cinnamate ester and an ethyl ester. It has been reported to be found in datura, galangal, and other organisms with available data.
Ethyl cinnamate is a multifunctional compound with applications in food, cosmetics, tissue clearing, and pharmaceutical research. As an orally active natural product from Kaempferia galanga, it has potential therapeutic applications in cancer and cardiovascular disease. Its anti-angiogenic activity through VEGFR2 attenuation is of particular interest for colorectal cancer research. It is also used as an analytical standard for research applications. The compound is for research use only. |
| Molecular Formula |
C11H12O2
|
|---|---|
| Molecular Weight |
176.21
|
| Exact Mass |
176.083
|
| CAS # |
103-36-6
|
| Related CAS # |
Ethyl cinnamate-d5;856765-68-9
|
| PubChem CID |
637758
|
| Appearance |
Colorless to off-white <6°C powder,>8°C liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
269.4±9.0 °C at 760 mmHg
|
| Melting Point |
6-8 °C(lit.)
|
| Flash Point |
148.6±9.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
2.71
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
179
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])=C([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)C([H])([H])C([H])([H])[H]
|
| InChi Key |
KBEBGUQPQBELIU-CMDGGOBGSA-N
|
| InChi Code |
InChI=1S/C11H12O2/c1-2-13-11(12)9-8-10-6-4-3-5-7-10/h3-9H,2H2,1H3/b9-8+
|
| Chemical Name |
ethyl (E)-3-phenylprop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (567.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6750 mL | 28.3752 mL | 56.7505 mL | |
| 5 mM | 1.1350 mL | 5.6750 mL | 11.3501 mL | |
| 10 mM | 0.5675 mL | 2.8375 mL | 5.6750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
